Regulus provides update on studies of oligonucleotides

Regulus Therapeutics announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis. Regulus is pursuing this effort in collaboration with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women’s Hospital and the Foundation for Neurologic Diseases. The early-stage collaboration began in September 2021, and has now advanced to evaluation of compounds of interest in ALS preclinical in vivo models. This milestone follows the successful completion of an oligonucleotide library and microglia cell-based screening campaign which identified compelling inhibitors of miR-155. Regulus and BWH are now evaluating the pharmacologic effects of selected anti-miR-155 inhibitors in preclinical ALS animal models, with an ultimate goal of achieving therapeutic efficacy and clinical translation for ALS patients. Preliminary data for these in vivo preclinical studies are expected in the second half of 2023.